• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hikma Pharmaceuticals Plc. (OP:HKMPY)

47.09 +0.08 (+0.17%)
Delayed Quote Updated: 9:51 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102
Open 47.09
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 47.01
Today's Range 47.09 - 47.09
52wk Range 31.80 - 49.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
March 26, 2026
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
News headline image
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
March 20, 2025
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada 
From Emergent BioSolutions
Via GlobeNewswire

Performance

52-Week Range 4.5% below 52-week high
47.09
31.8052W Low 49.3152W High
1 Week
45.681W Low 47.091W High

Hikma Pharmaceuticals Plc. (HKMPY) traded between $31.80 and $49.31 over the past 52 weeks and last traded at $47.09, 4.5% below its 52-week high. Over the past week it ranged between $45.68 and $47.09.

Past 12 Months
+3.0%
+10.8%
+1.9%
+20.1%
+12.8%
-1.7%
1W +$1.36
1M +$4.59
3M +$0.87
6M +$7.88
YTD +$5.36
1Y -$0.81

HKMPY was -1.7% over the past year, +20.1% over six months, +12.8% year to date, +3.0% in the last week.

12 Months vs Market
HKMPY
-1.7%
DIA
+9.2%
SPY
+10.4%
QQQ
+8.4%
IWM
+14.0%

Over the past 12 months HKMPY returned -1.7% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 0.40× 3-mo avg
Today 102 3-mo avg 254.0
1W
348.0
1M
321.0
3M
254.0
6M
353.0
YTD
990.0
1Y
2.2K

HKMPY most recently traded 102 shares against a 3-month average daily volume of 254.0.

More News

Read More
News headline image
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗
September 06, 2024
Via Benzinga
News headline image
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices ↗
August 28, 2024
Via Benzinga
News headline image
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
January 08, 2024
From Guardant Health, Inc.
Via Business Wire
News headline image
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape ↗
June 12, 2023
Via Benzinga
News headline image
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
December 26, 2022
From Junshi Biosciences
Via GlobeNewswire
News headline image
Friday Markets News ↗
March 25, 2022
Via Talk Markets
News headline image
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
August 27, 2021
From Bio-Thera Solutions, Ltd.
Via Business Wire
News headline image
Summer Friday ↗
June 25, 2021
Via Talk Markets

Frequently Asked Questions

Is Hikma Pharmaceuticals Plc. publicly traded?
Yes, Hikma Pharmaceuticals Plc. is publicly traded.
What exchange does Hikma Pharmaceuticals Plc. trade on?
Hikma Pharmaceuticals Plc. trades on the OTC Traded
What is the ticker symbol for Hikma Pharmaceuticals Plc.?
The ticker symbol for Hikma Pharmaceuticals Plc. is HKMPY on the OTC Traded
What is the current price of Hikma Pharmaceuticals Plc.?
The current price of Hikma Pharmaceuticals Plc. is 47.09
When was Hikma Pharmaceuticals Plc. last traded?
The last trade of Hikma Pharmaceuticals Plc. was at 11/03/26 09:51 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap